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Abstract
Background: The Framingham Heart Study (FHS) recently obtained initial results from the first genome-wide association scan
for renal traits. The study of 70,987 single nucleotide polymorphisms (SNPs) in 1,010 FHS participants provides a list of SNPs
showing the strongest associations with renal traits which need to be verified in independent study samples.
Methods: Sixteen SNPs were selected for replication based on the most promising associations with chronic kidney disease
(CKD), estimated glomerular filtration rate (eGFR), and serum cystatin C in FHS. These SNPs were genotyped in 15,747
participants of the Atherosclerosis in Communities (ARIC) Study and evaluated for association using multivariable adjusted
regression analyses. Primary outcomes in ARIC were CKD and eGFR. Secondary prospective analyses were conducted for
association with kidney disease progression using multivariable adjusted Cox proportional hazards regression. The definition of
the outcomes, all covariates, and the use of an additive genetic model was consistent with the original analyses in FHS.
Results: The intronic SNP rs6495446 in the gene MTHFS was significantly associated with CKD among white ARIC participants
at visit 4: the odds ratio per each C allele was 1.24 (95% CI 1.09–1.41, p = 0.001). Borderline significant associations of rs6495446
were observed with CKD at study visit 1 (p = 0.024), eGFR at study visits 1 (p = 0.073) and 4 (lower mean eGFR per C allele
by 0.6 ml/min/1.73 m2, p = 0.043) and kidney disease progression (hazard ratio 1.13 per each C allele, 95% CI 1.00–1.26, p =
0.041). Another SNP, rs3779748 in EYA1, was significantly associated with CKD at ARIC visit 1 (odds ratio per each T allele
1.22, p = 0.01), but only with eGFR and cystatin C in FHS.
Conclusion: This genome-wide association study provides unbiased information implicating MTHFS as a candidate gene for
kidney disease. Our findings highlight the importance of replication to identify common SNPs associated with renal traits.
Published: 3 June 2008
BMC Medical Genetics 2008, 9:49 doi:10.1186/1471-2350-9-49
Received: 29 February 2008
Accepted: 3 June 2008
This article is available from: http://www.biomedcentral.com/1471-2350/9/49
© 2008 Kottgen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Medical Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2350/9/49Background
Kidney disease aggregates within families and measures of
kidney function, such as estimated glomerular filtration
rate (eGFR), are heritable [1-4]. Whereas many monoge-
netic causes of kidney disease have been discovered, the
identification of common genetic variants hypothesized
to confer susceptibility to complex diseases, such as
chronic kidney disease (CKD), has been difficult and suf-
fers from a lack of replication of initial positive findings
[1,5].
Recently, genome-wide association studies (GWAS) to
discover associations of common genetic variants, single
nucleotide polymorphisms (SNPs), and a phenotype of
interest have become feasible. Surveying the whole
genomes of many individuals, preferably as part of a large
prospective study that provides extensive and rigorously
collected information on phenotypes, can provide unbi-
ased findings and has the power to potentially discover
common genetic variants that are associated with complex
diseases. So far, the method has successfully and repeat-
edly identified common SNPs associated with a wide vari-
ety of complex diseases such as diabetes mellitus and
coronary heart disease [6-11]. Because of the large
number of tests conducted and the small a priori probabil-
ity of a true association between any given SNP and the
phenotype, replication of initial findings from a GWAS is
essential [12].
Recently, genome-wide tests of 70,987 autosomal SNPs
with renal traits were conducted as part of the Framing-
ham Heart Study (FHS) 100 K SNP GWAS resource [13].
Initial results have been published [14], but have not been
replicated in independent study samples to date. None of
the initial associations between SNPs and CKD or eGFR
reached genome-wide significance. However, the initial
study had limited power, and true associations of moder-
ate size are likely to be associated at p-values on the order
of 10e-3 to 10e-5, as will be false positive associations due
to the large number of tests conducted. To distinguish true
from false positive findings, promising SNPs need to be
tested in independent cohorts. Therefore, the objective of
the present study was to validate initial findings by repli-
cating the strongest and most promising associations after
correction for multiple testing. Here we report the first
replication of initially observed associations from a GWAS
of kidney disease traits in 11,447 white participants of the
community-based, prospective Atherosclerosis Risk in
Communities (ARIC) Study.
Methods
Description of the initial (stage I) sample, Framingham 
Heart Study
Study sample
In 1948, 5,209 participants of the Framingham Heart
Study, a prospective community-based cohort, were
recruited into the Original Cohort. In 1971, 5,124 of their
children or spouses were enrolled into the Offspring
Cohort and examined every 4 to 8 years [15]. Members of
the largest 330 pedigrees among the Original and Off-
spring Cohorts were selected for genotyping (n = 1,345
after data cleaning) as detailed elsewhere [13]. Of these,
phenotype data from the Offspring examination 7 in
1998–2001 were available for 1,010 individuals with
eGFR and CKD and 981 individuals with cystatin C meas-
urements, the final sample sizes used for the stage I anal-
yses of the GWAS of renal traits [14]. The study was
approved by the Institutional Review Board of the Boston
University Medical Center. All subjects provided written
informed consent.
Genotyping
Genotyping was performed using the Affymetrix Gene-
Chip Human Mapping 100 K SNP set. Details of the gen-
otyping process are reported elsewhere [13]. All genotype
data were returned to the NHLBI; aggregate results data
are publicly available [16]. SNPs with call rates <80%,
deviations from Hardy-Weinberg expectations (p < 0.001
in unrelated individuals) or minor allele frequency <10%
were excluded. After data cleaning, 70,987 autosomal
SNPs remained for analyses [14].
Outcome definition
Estimated GFR (ml/min/1.73 m2) was calculated using
the four-variable Modification of Diet in Renal Disease
Study equation[17] from calibrated serum creatinine
measured at Offspring examination 7 by the modified
Jaffe method. CKD was defined based on the National
Kidney Foundation Kidney Disease Outcome Quality Ini-
tiative working group [18], and modified slightly, using
sex-specific cutoffs for CKD of eGFR<59 ml/min/1.73 m2
in women and <64 ml/min/1.73 m2 in men, as described
previously [14,19]. Serum cystatin C (mg/l) was measured
at Offspring examination 7 using particle enhanced
immunonephelometry (Dade Behring BN 100 nephelom-
eter) [14].
Statistical analysis
For data analysis, multivariable-adjusted residuals were
generated for each phenotype. Covariates used for multi-
variable-adjustment were age, sex, systolic blood pressure,
hypertension treatment, HDL-cholesterol, smoking, dia-
betes, and body mass index [20]. To account for related-
ness among the study individuals, generalized estimating
equations (GEE) or family-based association tests (FBAT)Page 2 of 12
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als and each SNP; a detailed description is provided else-
where [13]. Additional analyses re-analyzed SNPs that
replicated in ARIC using the raw traits in multivariable
adjusted GEE regression models to allow for a direct com-
parison of effect size estimates between the two studies.
Selection of SNPs for replication
Strongly associated SNPs in the FHS 100 K analyses were
prioritized for follow-up genotyping in an independent
sample, the ARIC Study (described below) as shown in
Figure 1. Ten SNPs showed joint association with all three
kidney traits (eGFR, CKD, cystatin C) at p < 0.01 for each
trait. Eight of these 10 SNPs were selected for follow-up
genotyping; the remaining 2 were dropped due to high
linkage disequilibrium (LD) with other SNPs in this set. In
addition, statistical and biological evidence were com-
bined by selecting a subset of SNPs showing strong asso-
ciation and additional location in candidate gene regions.
Eight SNPs met these criteria, and were selected from the
following sets: 1) SNPs with the 100 lowest p-values from
GEE models for association with one of the 3 kidney
traits; 2) SNPs that showed association with both eGFR
and cystatin C at p-values <0.01 from either GEE or FBAT
models; 3) SNPs that showed association with both eGFR
and CKD at p-values <0.01 from either GEE or FBAT mod-
els. Only SNPs with a minimum call rate of 90% were con-
sidered for replication. Candidate genes were identified as
auch if, based on a thorough literature search, there was
evidence for the gene's involvement in renal disease (for
example, a renal phenotype in knock-out mice or muta-
tions causing a Mendelian syndrome in humans with
renal involvement), or if their gene products are known to
be involved in a physiological mechanism important for
kidney function such as filtration or electrolyte transport.
The SNPs selected for replication for their location in or
near a candidate gene were located in
FRAS1,[21]NR3C2,[22]SGK1,[23]CFTR,[24]EYA1,[25]IQ
GAP1,[26,27] and near GLIS3[28].
Description of the replication (stage II) sample, 
Atherosclerosis in Communities Study
Study sample
The ARIC Study is an ongoing, population-based, pro-
spective cohort of 15,792 adults. Study participants were
aged 45–64 years at their recruitment from four US com-
munities in 1987–89, when they underwent the standard-
ized ARIC baseline examination (visit 1). Participants
underwent 3 further standardized examinations approxi-
mately every 3 years. Since the end of visit 4 in 1998, par-
ticipants continue to be followed up by annual phone
calls as well as by obtaining information from hospitali-
Selection process of SNPs from the FHS 100 K GWAS screen to be followed up by genotyping in the ARIC cohortFigure 1
Selection process of SNPs from the FHS 100 K GWAS screen to be followed up by genotyping in the ARIC 
cohort. Abbreviations: GWAS: genome-wide association, SNPs: single nucleotide polymorphisms, GEE: generalized estimating 
equation, FBAT: family-based association test, CKD: chronic kidney disease, eGFR: estimated glomerular filtration rate, cys: 
cystatin C.
Clean 100K GWAS data:
1,345 FHS 
family members 
70,987 SNPs
Multiple related traits screen:
p<0.01 in GEE or FBAT with
all 3 kidney traits
(CKD, cys, eGFR, n=10)
Location in a candidate gene 
and
1) lowest 100 p-values for each trait:
( p<0.001, n=292)
or
2) two overlapping traits
(CKD&eGFR, n=135; cys&eGFR, n=98)
Replication:
de novo genotyping of 16 SNPs
in 11,447 white and 4,253
black ARIC participants
n=8 SNPs
n=8 SNPsPage 3 of 12
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tificates. Further details of the study design have been
reported previously [29]. Institutional Review Boards of
the participating institutions approved the study proto-
cols, and written informed consent was obtained from all
participants at each examination. From the total study
sample of 15,792 participants at the baseline examina-
tion, 45 individuals were excluded because they did not
consent to genetic research and 47 because they did not
self-identify as "black" or "white". As the genotyped FHS
participants were exclusively white, the primary replica-
tion sample consisted of white ARIC participants. Black
ARIC participants were also genotyped, enabling further
characterization of SNPs showing evidence of association
in white ARIC participants. Measures of genotyping qual-
ity control and allele distributions were assessed in 11,447
white and 4,253 black ARIC participants. For association
analyses, participants were additionally excluded for gen-
otyping failure of all SNPs (173 whites, 168 blacks), and
for missing serum creatinine (4 whites, 97 blacks) and
missing covariates (53 whites, 94 blacks) at visit 1 [miss-
ing creatinine (76 whites, 77 blacks) and missing covari-
ates (15 whites, 135 blacks) at visit 4] for a final, primary
replication study sample of 11,217 white participants at
visit 1 [8,717 at visit 4] (Table 1), and additionally 3,894
black participants at visit 1 [2,358 at visit 4] [see Addi-
tional file 1].
Assessment of other study characteristics
Detailed information on obtaining demographic, socioe-
conomic, health behavior, risk factor control, and medical
history have been described previously [29,30]. Racial
affiliation was self-reported using the terms "black" or
"white".
Genotyping
Genotyping of all SNPs was performed by the ARIC Cen-
tral DNA Laboratory. The polymorphisms rs10509132,
rs2827732, rs6495446, rs1743955, and rs4835136 were
genotyped individually using the TaqMan assay (Applied
Biosystems, Foster City, CA). All other SNPs were geno-
typed in two multiplexes using the iPLEX gold assay
(Sequenom, San Diego, CA). The minimum satisfactory
call rate was set at 90%, and the cutoff indicating statisti-
cally significant deviation from Hardy-Weinberg expecta-
tions was set at p < 10-4.
Outcome definitions
Continuous eGFR and CKD, defined as in FHS, were
defined a priori as the primary study outcomes. These out-
comes were investigated primarily at ARIC visit 4 which
provided more individuals with CKD and a distribution
of major kidney disease risk factors, such as hypertension,
similar to that in FHS. Outcomes were also investigated at
ARIC visit 1 to maximize the sample size for continuous
outcomes. Serum cystatin C measurements were not avail-
able in the ARIC Study. In secondary analyses, associa-
tions between the SNPs and kidney disease progression
were conducted, as were analyses defining CKD as eGFR
<60 ml/min/1.73 m2 [18]. Serum creatinine was meas-
ured using the modified kinetic Jaffe reaction and creati-
nine values were standardized and calibrated as described
previously [31,32]. Kidney disease progression was
defined as either an increase in serum creatinine levels ≥
Table 1: Study Characteristics by Study Sample
Framingham Heart Study ARIC whites
Examination 7 Visit 1 Visit 4
Characteristic
Sample size n 1007 11217 8717
Age, years 58.5 (9.6) 54.4 (5.7) 63.1 (5.6)
Male, % 49.1 47.2 46.3
Systolic blood pressure, mmHg 125 (18.5) 118.5 (17) 125.5 (18)
Antihypertensive medication, % 31.2 25.8 31.4
Diabetes mellitus, % 11.2 9.1 13.9
Body mass index, kg/m2 28.4 (5.8) 27.0 (4.9) 28.3 (5.2)
Current smokers, % 14.2 24.8 14.1
High density lipoprotein cholesterol, mg/dl 52.6 (16.1) 50.4 (16.8) 49.0 (16.3)
Serum creatinine, mg/dl 0.88 (0.28) 0.85 (0.20) 0.91 (0.24)
eGFR, ml/min/1.73 m2 86.6 (19.8) 89.6 (17.9) 80.5 (16.9)
Prevalent CKD*, n (%) 80 (8.0) 449 (4.0) 756 (8.7)
Incident CKD†, n N/A N/A 843
Serum cystatin C, mg/l 0.96 (0.24) N/A N/A
Data are presented as mean (standard deviation) for continuous and proportion for categorical variables for individuals with information on all 
characteristics available at FHS Offspring exam 7 and ARIC visits 1 and 4. *CKD was defined as eGFR <59 ml/min/1.73 m2 (women) and <64 ml/min/
1.73 m2 (men). †For definition of incident CKD and duration of follow-up see methods section. Abbreviations: eGFR: estimated glomerular filtration 
rate, CKD: chronic kidney disease.Page 4 of 12
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death coded for chronic renal disease using international
classification of disease codes and analyzed as described
elsewhere [30].
Statistical analysis
Consistent with FHS, an additive genetic model was used
for each SNP in all analyses. Multivariable regression
models were adjusted for the same covariates as in FHS.
For the secondary analyses using prospective data, follow-
up time was counted from the baseline ARIC visit until the
date kidney disease progression occurred in cases, or the
earlier of the date of last contact (or date of non-CKD
death) or December 31, 2004 for non-cases. Multivariable
adjusted Cox Proportional Hazards models were used,
and the proportionality assumption of all Cox models
was assessed by inspection of the complementary log(-log
[survival function]) curves.
The two-sided significance level was determined a priori at
α = 0.05 for each of the 8 SNPs in plausible candidate
genes and at α = 0.00625 (0.05/8) after applying a Bonfer-
roni correction to the other 8 SNPs. In our analyses
among white participants, the power to detect an odds
ratio of CKD of 1.3 or higher per each increase in risk
allele and assuming α = 0.05 is >80% for a risk allele fre-
quency of 0.2, and >90% for a risk allele frequency of 0.3.
Results
Table 1 shows the distribution of study sample character-
istics among FHS and white ARIC participants, and Addi-
tional file 1 shows this distribution among the additional
study sample of black ARIC participants. The mean eGFR
in FHS participants was 86.6 ml/min/1.73 m2 (standard
deviation (SD) 19.8), compared to 89.6 ml/min/1.73 m2
(SD 17.9) in white ARIC participants at visit 1 and 80.5
ml/min/1.73 m2 (SD 16.9) at visit 4. CKD was present in
80 (7.9%) of FHS participants and in 449 (4.0%) of white
ARIC participants at visit 1 and 756 (8.7%) at visit 4.
Minor allele frequencies for the 16 SNPs among FHS and
white ARIC participants are provided in Table 2, and
minor allele frequencies among black ARIC participants
are provided separately [see Additional file 2]. The minor
allele frequencies in FHS and white ARIC participants
were similar, and both were similar to the minor allele fre-
quencies from the HapMap CEU sample. The distribution
of genotypes for all SNPs in ARIC whites conformed to
Hardy-Weinberg expectations, while in ARIC blacks,
rs2228210 and rs6831700 did not and were excluded
from further analyses. The average call rate across SNPs
was 94.1% in white and 91.6% in black ARIC participants.
The concordance rates for genotyping of 314 replicate
samples per SNP in ARIC was >97% for each SNP (kappa
coefficient ≥ 0.95).
Table 2: Minor allele frequencies for all SNPs genotyped in 1,345 FHS and 11,447 white ARIC participants
n MAF
SNP gene location FHS ARIC white FHS ARIC white
Selected for low p-value only
rs4553158 MIER1 chr1:67148467 1,219 10,685 0.13 (G) 0.17 (G)
rs6831700 WDR19 chr4:39079530 1,273 10,808 0.34 (G) 0.33 (G)
rs2419912 (BC047601) chr5:157777113 1,341 10,817 0.49 (C) 0.46 (C)
rs2228210 HIVEP1 chr6:12230160 1,252 10,782 0.29 (G) 0.36 (G)
rs10509132 ANK3 chr10:61995671 1,223 10,783 0.45 (G) 0.48 (G)
rs1613631 KRT84 chr12:51062202 1,330 10,782 0.20 (G) 0.20 (G)
rs6495446 MTHFS chr15:77942037 1,328 10,816 0.24 (T) 0.27 (T)
rs2827732 gene desert chr21:23107838 1,344 10,768 0.19 (A) 0.16 (A)
Selected as a candidate
rs2061063 FRAS1 chr4:79591766 1,322 10,747 0.33 (G) 0.35 (G)
rs4835136 NR3C2 chr4:149627601 1,334 10,990 0.36 (T) 0.37 (T)
rs1743955 SGK1 chr6:134562589 1,299 10,763 0.42 (T) 0.39 (T)
rs4148686 CFTR chr7:116728468 1,225 10,795 0.17 (G) 0.20 (G)
rs3779748 EYA1 chr8:72410728 1,342 10,789 0.32 (C) 0.33 (C)
rs1455177 BC047388 chr9:3782613 1,337 10,434 0.45 (G) 0.45 (G)
rs10520688 IQGAP1 chr15:88752520 1,331 10,814 0.15 (G) 0.14 (G)
rs2839235 PCNT chr21:46625020 1,300 10,799 0.14 (C) 0.13 (C)
To facilitate interpretation, alleles were transferred to the strand typed in ARIC if they were typed on the opposite strand in FHS. The sample size 
n presented here is for all successfully genotyped individuals irrespective of whether all covariates for regression analyses were available. 
Abbreviations: SNPs: single nucleotide polymorphisms, n: sample size, MAF: minor allele frequency.Page 5 of 12
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Study
Table 3 shows the replication data for the 16 selected
SNPs at visit 4, where participants were on average 9 years
older than at visit 1, thus providing a greater number of
participants with CKD. Among the 8 SNPs associated with
all 3 renal traits in FHS, rs6495446 in MTHFS was signifi-
cantly associated with CKD among white ARIC partici-
pants (odds ratio (OR) 1.24 per each C allele, 95%
confidence interval 1.09–1.41, p = 0.001). The association
with eGFR at visit 4 (-0.57 ml/min/1.73 m2 per increase in
C allele, p = 0.043) was not significant at the pre-specified
α of 0.00625. The proportion of eGFR variance explained
by rs6495446 was 0.04% (0.4% in FHS). The associations
of rs6495446 with CKD and eGFR were of similar magni-
tude but not statistically significant at ARIC visit 1 (OR of
CKD 1.20 per increase in C allele, p = 0.024, -0.48 ml/
min/1.73 m2 per increase in C allele, p = 0.073) [see Addi-
tional file 3]. The direction of the association results for
rs6495446 was consistent with the one observed in FHS,
therefore replicating the association of this SNP with
CKD. Further investigation of this SNP in black ARIC par-
ticipants revealed no significant association of rs6495446
and either trait at visit 4 (p = 0.68 for CKD and p = 0.26
for eGFR) or visit 1 (p = 0.44 for CKD and p = 0.03 for
eGFR), although the association of rs6495446 and eGFR
at visit 1 in ARIC blacks was of borderline significance (-
1.2 ml/min/1.73 m2 per increase in T allele, p = 0.03).
None of the other 7 SNPs associated with all 3 renal traits
in FHS were significantly associated with either kidney
trait in white ARIC participants at visit 4 (Table 3).
Among the SNPs selected for their location in a candidate
gene, rs3779748 (EYA1) was significantly associated with
CKD not at ARIC visit 4 but at visit 1 (OR 1.22 per each
increase in T allele, p = 0.01) [see Additional file 3]. The
same risk allele had been observed in FHS. However, since
rs3779748 had been significantly associated with only the
traits eGFR and cystatin C but not CKD in FHS, this does
not constitute a true replication. Another SNP,
rs10520688 in IQGAP1, was significantly associated with
CKD at ARIC visit 4 (p = 0.02), but the risk allele was
opposite from the one observed in FHS. None of the other
SNPs selected for their location in a candidate gene was
significantly associated with either kidney trait in ARIC.
Secondary analyses
In secondary analyses, the association of all 16 SNPs was
investigated prospectively with kidney disease progres-
sion in ARIC. Over a mean follow-up of 14.7 years, there
were 836 white ARIC participants with kidney disease pro-
gression. None of the SNPs was significantly associated
with kidney disease progression among white ARIC par-
ticipants at the pre-specified levels of significance. How-
ever, the SNP rs6495446 (MTHFS), which replicated
among white ARIC participants for the association with
CKD, showed a hazard ratio of 1.13 per each increase in C
allele for kidney disease progression (95% CI 1.01–1.26,
p = 0.041). The proportional hazards assumption was
met.
We further investigated the association of rs6495446 and
CKD at ARIC visit 4 stratified by sex as well as by age (<60
years, ≥ 60 years). In these hypothesis-generating analy-
ses, we observed stronger effects in men (OR = 1.32, 95%
CI 1.11–1.57) compared to women (OR = 1.15, 95% CI
0.95–1.40; p-interaction = 0.33) and in participants aged
<60 years (OR = 1.54, 95% CI 1.12–2.11) compared to
those aged ≥ 60 years (OR = 1.16, 95% CI 1.01–1.34; p-
interaction = 0.09).
For SNP rs6495446, which had replicated among the
ARIC white sample, the FHS data were re-analyzed in sec-
ondary analyses using multivariable regression of the raw
trait in order to parallel the analyses conducted in ARIC,
thus allowing for a direct comparison of effect size esti-
mates. Per each increase in C allele, the OR of CKD was
1.91 (95% CI 1.22–2.99, p = 0.005), and mean eGFR was
lower by 3.1 ml/min/1.73 m2 (95% CI 1.2–5.0, p =
0.001). Figure 2 shows these risk estimates in relation to
the risk estimates obtained for eGFR (panel A) and CKD
(panel B) in ARIC, as well as in relation to the risk esti-
mates obtained from prospective analyses in ARIC.
We also conducted sensitivity analyses in the ARIC Study
using an overall cutoff of eGFR <60 ml/min/1,73 m2 to
define CKD in order to evaluate the most commonly used
clinical definition of CKD [18]. While the direction of the
association of rs6495446 and CKD in ARIC whites at
study visit 4 was consistent and the magnitude largely
unchanged, the odds ratio was no longer statistically sig-
nificant (OR 1.12, p = 0.075) as it had been using the sex-
specific cutoffs.
Discussion
Here we present results from the first complete GWAS of
renal traits, comprised of results from FHS, the discovery
sample (stage I) [14], and the large population-based
ARIC Study, the replication sample (stage II). The associa-
tion of SNP rs6495446 in MTHFS with CKD replicated in
white ARIC participants at study visit 4. Another SNP,
rs3779748 in EYA1, was significantly associated with CKD
at study visit 1, a kidney trait different from but related to
the ones significantly associated in FHS, eGFR and cysta-
tin C. Our findings may provide guidance for investigators
wishing to further replicate the associations from this
GWAS of renal traits, as well as present considerations and
mechanisms of SNP selection for replication studies.Page 6 of 12
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Table 3: Replication data of 16 SNPs significantly associated with renal traits on the FHS 100 K chip in 8,717 white participants at ARIC 
visit 4.
SNP Gene Strand Alleles* MAF FHS ARIC
FHS/ARIC FHS ARIC Trait List† Trait GEE p-value FBAT p-value GLM p-value
Selected for low p-value only
rs4553158 MIER1 -/+ A/G 0.13(C) 0.17(G) 1,2,3,4 CKD 4.3xe-4 0.739 0.749
cys 0.006 0.432 --
eGFR 0.003 0.914 0.300
rs6831700 WDR19 -/+ G/T 0.34(C) 0.33(G) 1 CKD 0.004 0.001 0.361
cys 0.344 0.005 --
eGFR 0.034 0.001 0.472
rs2419912 (BC047601) +/+ T/C 0.49(C) 0.46(C) 1 CKD 0.002 0.144 0.044
cys 0.003 0.030 --
eGFR 9.4xe-5 0.342 0.026
rs2228210 HIVEP1 +/+ A/G 0.29(G) 0.36(G) 1,2,3 CKD 0.017 0.007 0.805
ns cSNP cys 0.003 0.027 --
eGFR 2.3xe-4 0.005 0.520
rs10509132 ANK3 +/+ G/T 0.45(G) 0.48(G) 1,2,3 CKD 0.009 0.855 0.609
cys 0.002 0.002 --
eGFR 0.002 0.031 0.349
rs1613631 KRT84 -/+ T/G 0.2(C) 0.20(G) 1,2,3 CKD 0.048 0.002 0.360
cys 0.177 0.009 --
eGFR 0.013 0.003 0.169
rs6495446 MTHFS +/+ C/T 0.24(T) 0.27(T) 1,2,3 CKD 0.003 0.429 0.001
cys 0.006 0.149 --
eGFR 0.001 0.167 0.043
rs2827732 gene desert -/+ C/A 0.19(T) 0.16(A) 1,2,3 CKD 0.001 0.004 0.403
cys 0.002 4.9 × 10-4 --
eGFR 0.002 0.025 0.806
Selected as a candidate
rs2061063 FRAS1 -/- G/C 0.33(G) 0.35(G) 2 CKD 0.009 0.015 0.149
cys 0.402 0.790 --
eGFR 0.009 0.018 0.719
rs4835136 NR3C2 -/+ C/T 0.36(A) 0.37(T) 2,5 CKD 0.003 0.002 0.380
cys 0.971 0.260 --
eGFR 0.001 0.001 0.920
rs1743955 SGK1 -/+ T/C 0.42(A) 0.39(T) 3 CKD 0.707 0.459 0.164
cys 0.096 0.004 --
eGFR 0.006 0.007 0.889
rs4148686 CFTR -/+ C/G 0.17(C) 0.20(G) 4 CKD 1.1xe-4 0.209 0.543
cys 0.914 0.291 --
eGFR 0.060 0.555 0.353
rs3779748 EYA1 +/+ T/C 0.32(C) 0.33(C) 3 CKD 0.128 0.826 0.882
cys 0.008 0.435 --
eGFR 0.006 0.593 0.788
rs1455177 BC047388 +/- C/G 0.45(C) 0.45(G) 6 CKD 0.113 0.494 0.208
(GLIS3) cys 6.0xe-4 0.045 --
eGFR 0.059 0.669 0.404
rs10520688 IQGAP1 +/- T/C 0.15(C) 0.14(G) 3 CKD 0.043 0.837 0.020
cys 0.004 0.608 --
eGFR 0.003 0.82 0.674
rs2839235 PCNT +/+ T/C 0.14(C) 0.13(C) 3,5 CKD 0.028 0.134 0.848
cys 0.016 0.006 --
eGFR 1.6xe-5 0.055 0.827
The upper part of the table contains the SNPs selected for replication based on a low p-value (<0.01) for association with all of the 3 kidney traits in FHS, while 
the lower part of the table contains the SNPs that were selected for their location in a candidate gene.
*Polymorphic nucleotides (alleles) are listed with respect to the (+) strand relative to the human reference sequence with the nucleotide in the reference 
sequence listed first; strand information refers to this reference sequence. †Trait lists: 1: all 3 traits, 2: CKD&eGFR, 3: cys&eGFR, 4: CKD, 5: eGFR, 6: cys. 
Statistical significance for replication was determined a priori at p = 0.00625 for SNPs selected based on p-value and 0.05 for SNPs selected as candidates. P-values 
shown for ARIC are derived from all participants not missing any covariates (n = 8,717), sample size varies slightly due to missing individual SNPs. Annotation 
based on USCS Genome Browser, assembly March 2006 (NCBI Build 36.1). Gene names in italics indicate the SNP is located in the gene, parentheses indicate 
proximity to a gene or mRNA, SNPs more than 400 kb away from the closest known gene or mRNA are defined as located in a gene desert. Abbreviations: MAF: 
minor allele frequency, GEE: generalized estimating equation, FBAT: family-based association test, GLM: generalized linear model, CKD: chronic kidney disease, 
cys: cystatin C, eGFR: estimated glomerular filtration rate, ns cSNP: non-synonymous coding SNP.
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since this is the first study presenting replicated results
from a GWAS of renal traits. Apart from the results in FHS,
another study has published initial but not replicated
association results from genome-wide tests for the traits
serum creatinine, eGFR, and creatinine clearance in 2,000
white hypertensive individuals [33]. Findings on the asso-
ciation of specific SNPs with serum creatinine or eGFR
were not presented as none of these associations met the
significance threshold for further investigation of p < 10-5
chosen by the authors [33].
SNP rs6495446, an intronic SNP in the gene MTHFS on
chromosome 15q25.1, was significantly associated with
CKD in white ARIC participants at study visit 4 (OR 1.24
per each C allele, 95% confidence interval 1.09–1.41, p =
0.001), replicating the trait and risk allele observed in the
initial screen. Comparison of the effect sizes as well as the
proportion of eGFR variance explained by rs6495446
between the FHS and white ARIC samples showed greater
magnitude of the effects in FHS, consistent with the phe-
nomenon of the "winner's curse": associations in the rep-
lication sample are often of lesser magnitude than in the
initial sample, especially in samples with relatively low
power to detect moderate effect sizes, because only the
strongest associations in this initial sample were selected
to be followed up. Further replication of the association of
MTHFS rs6495446 and CKD in additional studies is war-
ranted, particularly in light of the small effect size
observed in the replication and the fact that the associa-
tion reached statistical significance at the pre-specified
level for one but not both traits and visits studied in ARIC.
The gene MTHFS codes for the enzyme methenyltetrahy-
drofolate synthetase, which is expressed in human and rat
kidney and has been reported to play a role in folate turn-
over and accumulation [34]. To our knowledge, there
have not been any prior reports linking this gene to renal
traits or kidney disease, although folate supplementation
is known to reduce homocysteine levels, which are com-
monly elevated in individuals with advanced kidney dis-
ease [35,36]. The SNP rs6495446 is located in intron 2 of
MTHFS. The only coding SNP in MTHFS provided in the
public database dbSNP is rs8923 in exon 3 (T202A); this
SNP was not included on the genotyping chip. In the Hap-
Map CEU sample, rs8923 and rs6495446 are grouped
Results from multivariable adjusted association analyses of rs6495446 in MTHFS and both eGFR (panel A) and CKD (panel B) in FHS and ARICFig re 2
Results from multivariable adjusted association analyses of rs6495446 in MTHFS and both eGFR (panel A) and 
CKD (panel B) in FHS and ARIC. Risk estimates refer to each additional copy of the C allele. For ARIC, odds ratios of 
CKD per risk allele and the hazard ratio of kidney disease progression per risk allele are presented on the same scale. Hori-
zontal bars represent 95% confidence intervals. Abbreviations: eGFR: estimated glomerular filtration rate, OR: odds ratio, 
CKD: chronic kidney disease.
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ingly, when we searched a database containing results
from a GWAS of global gene expression [37], the associa-
tion of the rs6495446 C allele with higher expression lev-
els of a MTHFS gene transcript was genome-wide
significant (p = 3.3 × 10-10). The coding variant rs8923
was not genotyped in this study, but its location is flanked
on both sides by the two markers showing the strongest
association with MTHFS transcript levels out of all
408,273 SNPs investigated. rs6495446 by itself accounted
for 13% of the total expression variance of this MTHFS
transcript [38]. Although this observation does not allow
for the conclusion that altered MTHFS mRNA levels asso-
ciated with rs6495446 are causally related to kidney dis-
ease, it provides some functional evidence for rs6495446
or a variant in LD with it. Upcoming denser GWAS may
help to further fine-map the observed association
Another SNP significantly associated with CKD in ARIC
whites at visit 1, rs3779748, is located in the gene eyes
absent homolog 1 (Drosophila) (EYA1) on chromosome
8q13.3. Mutations in EYA1 cause the Mendelian syn-
drome branchiootorenal dysplasia syndrome (MIM#
113650) featuring a renal phenotype ranging from mild
renal hypoplasia to complete absence of the kidneys [25].
Although the same risk allele for rs3779748 was identified
in both FHS and ARIC whites, this SNP was associated
only with the traits eGFR and cystatin C in FHS. Although
CKD and eGFR are highly correlated traits in ARIC, the
observed association should therefore not be considered a
true replication. Moreover, the association with CKD at
ARIC visit 1 was no longer observed at ARIC visit 4, and
we can therefore not exclude a chance finding.
Strengths of the work presented here include high power
for replication of the association between common
genetic variants and renal traits, as well as the availability
of a replication study similar in design to the FHS Study,
namely another community-based, prospective study
with rigorously collected phenotype information. We
were therefore able to adjust our analyses for the same
covariates as FHS, leading to better comparability of the
results across studies. Finally, we were able to prospec-
tively evaluate the association with incident kidney dis-
ease progression in secondary analyses.
When interpreting the findings presented here, several
limitations should be kept in mind. First, there are limita-
tions to the original 100 K genome-wide screen for renal
traits in FHS, which are discussed in detail elsewhere
[13,14]. Among them is the limited power to discover
moderate genetic effects of the size we observed
(OR~1.2), especially for dichotomous but also for contin-
uous traits. It may therefore be expected that future, better
powered screens will identify additional variants of com-
parable effect size that could not be detected in the FHS
100 K screen. Further, the FBAT test is underpowered as it
only relies on a subset of informative families. Therefore,
FBAT results should not be interpreted with the same
degree of confidence as GEE results. Despite these limita-
tions, however, this genome-wide screen successfully
identified a SNP in CST3, the gene encoding the cystatin
C protein, as associated with serum cystatin C levels at
genome-wide significance [14]. This increases confidence
that the FHS 100 K genome-wide screen was able to iden-
tify associations which may represent true findings.
Another potential limitation in the initial genome-wide
screen was the use of a liberal call rate of 80%. We tried to
address this in our replication study by using only those
SNPs having call rates >90% in FHS. Moreover, SNPs with
minor allele frequencies <10% were excluded from the
initial association analyses in FHS, as an excess number of
significant results was observed for SNPs with low minor
allele frequencies [13]. We could therefore not investigate
a putative contribution to the phenotypic variation by rare
genetic variants, as has been reported for other complex
genetic traits [39]. However, genome-wide association in
general is not a good technique for detecting rare variants
[40].
We further cannot exclude the possibility that undetected
population stratification might have influenced our
results, but prior investigations within FHS have found no
evidence for the presence of population stratification [13].
In addition, the magnitude of the association between
rs6495446 and CKD in ARIC did not differ significantly
by ARIC Study center (p-interaction = 0.3).
Secondly, the selection of only 16 SNPs for further geno-
typing might not be sufficient for a comprehensive evalu-
ation of all strongly associated SNPs from the FHS 100 K
genome-wide association scan of renal traits. In particular,
the selection and examination of a single SNP for a given
genetic region may not be sufficient to capture the full
effect of genetic variation in this region. Despite good
power to detect significant associations between common
SNPs and renal traits in ARIC, we observed true replica-
tion for only one of the selected SNPs, rs6495446. This
may have been influenced by the selection strategy we
used to prioritize SNPs for follow-up genotyping. A for-
mal comparison between SNPs selected based on joint
association with related phenotypes and those selected
based on low p-values and biologic reasons is limited by
the small number of selected SNPs, but our data does not
lend strong support to either strategy. The results pre-
sented here, specifically for rs6495446 in MTHFS, should
be further replicated and additional variants in MTHFS
should be genotyped in future studies for fine-mapping of
the association before a definite conclusion about the
presence or absence of a moderate-sized associationPage 9 of 12
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drawn.
Limitations to the phenotype definition include the lack
of serum cystatin C measurements in ARIC as well as esti-
mation of GFR. Although serum creatinine measurements
were calibrated in both FHS and ARIC using the same
method, GFR estimation based on serum creatinine has
inherent limitations including lower accuracy in the
higher GFR ranges [41]. We tried to address this issue by
selecting SNPs for replication that were significantly asso-
ciated with more than one renal trait in FHS, and in fact
50% of the SNPs selected for further genotyping in ARIC
were associated with all 3 kidney traits investigated in
FHS.
Conclusion
In summary, the association of SNP rs6495446 in MTHFS
with CKD was replicated in an independent study sample
of white ARIC participants, constituting the first GWAS of
kidney disease traits including both discovery and replica-
tion. Further work is needed to fully characterize the asso-
ciation of genetic variants in MTHFS with kidney disease.
These findings highlight the importance of replication of
initial GWAS findings to identify common SNPs associ-
ated with renal function traits.
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